Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK's Belantamab Among Drugs Seeking EU Approval Nod

Second Time Around For GSK's BCMA-Targeting Therapy

Executive Summary

GlaxoSmithKline's potential multiple myeloma treatment is one of several new products that could get an EU marketing thumbs up from the European Medicines Agency this week.

You may also be interested in...



EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab

GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.

GW Pharma Among Myriad Hopefuls Seeking Extended Indications In EU

Applications to widen the therapeutic indications of up to 20 approved drugs will be decided on this week at the European Medicines Agency.

EMA’s CHMP Is Set To Adopt Position On Another Avastin Biosimilar

The market for biosimilar Avastin is set to form imminently, with two players holding final approvals from the European Commission waiting in the wings. In the coming days, the EMA’s Committee for Medicinal Products for Human Use is likely to issue an opinion on a further application.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel